Cannabis & CBD Compliance — Federal + California
Every rule currently governing how retailers, pharmacies, dispensaries, and manufacturers may sell, produce, market, and handle cannabis and cannabinoid products in California — with risk ratings and penalty exposure.
⚠ Three changes are actively reshaping this landscape right now
1. Federal hemp redefinition takes effect November 12, 2026 (P.L. 119-37 § 781). Any finished hemp product with more than 0.4 mg total THC per container, or any cannabinoid synthesized outside the plant, stops being "hemp" and becomes a Schedule I controlled substance. This is roughly 99 days away and captures most of the hemp-derived market.
2. California AB 8 Phase 1 is already in force (since January 1, 2026). Inhalable hemp is banned outright; hemp extract in food, beverage, or supplements must be >99% pure isolate with zero detectable THC. Full-spectrum CBD is gone from general retail.
3. Partial federal rescheduling landed April 28, 2026. FDA-approved marijuana drug products and state-licensed medical marijuana moved to Schedule III. Adult-use marijuana remains Schedule I. This changes the 280E tax picture for medical operators but not the criminal-law picture for adult-use.
| Business type | Overall risk | Dominant exposure | Realistic worst case |
|---|---|---|---|
| General retailer (grocery, convenience, wellness, smoke shop) |
CRITICAL | Selling non-compliant hemp inventory post-AB 8; federal contraband exposure after Nov 12, 2026; unsubstantiated health claims on shelf talkers and social. | Inventory seizure and embargo, civil penalties stacking daily, tobacco-license revocation, and — after Nov 12 — possession of a Schedule I controlled substance. |
| Pharmacy | HIGH | Professional-license exposure is the asymmetric risk: a $500 product decision can jeopardize a PharmD license and DEA registration. Health claims from a licensed professional draw far more FDA/FTC scrutiny. | Board of Pharmacy discipline, DEA registration action, FDA warning letter naming the pharmacist, FTC penalties, plus loss of professional liability coverage. |
| Licensed dispensary (DCC retail / microbusiness) |
HIGH | Track-and-trace reconciliation, advertising audience-composition proof, packaging/labeling, local permit conditions, excise-tax remittance. | DCC fines up to $30,000/day stacked per violation, license suspension or revocation, CDTFA tax assessment, local permit loss. |
| Manufacturer / producer | CRITICAL | Product formulation legality under the new federal definition, extract purity mandate, CDPH registration, testing and COA integrity, packaging compliance. | Entire product line becomes federally illegal on Nov 12, 2026; recall, seizure, injunction, criminal referral, and total loss of finished-goods inventory. |
| Distributor / wholesaler | HIGH | Interstate shipment of products that lose hemp status; track-and-trace custody; testing gatekeeping obligations. | Federal trafficking exposure on interstate shipments, DCC discipline, cargo seizure. |
| Marketer / affiliate / content | HIGH | FTC substantiation and disclosure, FDA disease-claim exposure, CA audience-composition rules, testimonial rules. | $53,088 per violation FTC civil penalties, FDA warning letter, state UCL/FAL action, platform deplatforming. |